INTRODUCTION {#s1}
============

Bacterial cancer therapy relies on the natural propensity of certain bacteria, including *Escherichia coli* \[[@R1]\], *Salmonella* \[[@R2]\], *Clostridium* \[[@R3]\], and *Listeria* \[[@R4]\], to accumulate and replicate in various types of tumors \[[@R5]\]. However, the strains must be modified to eliminate factors responsible for bacteria-related toxicity, i.e., products of virulence genes and obvious endotoxins. In the case of *Salmonella typhimurium*, the first such strain (VNP20009) used for cancer therapy carried a mutation in *msbB*, which altered lipid A structure, and *purI*, to confer purine auxotrophy \[[@R6]--[@R8]\]. Another strain used in this context is the A1-R mutant, a leucine--arginine auxotroph with elevated antitumor activity that arose during selection by tumor passage \[[@R9]--[@R14]\]. This strain exerts extraordinary antitumor effects in patient-derived orthotopic xenograft mouse models, especially in combination with chemotherapy \[[@R15]--[@R24]\]. This feature is ascribed to the ability of this strain to induce quiescent cancer cells to cycle, rendering them chemosensitive \[[@R25], [@R26]\].

In our studies, we have used the ΔppGpp strain of *Salmonella typhimurium*, which lacks both genes encoding ppGpp synthesis enzyme, *relA* and *spot* \[[@R27]--[@R29]\], because this strain is capable of targeting all solid tumors tested but is almost a million-fold less virulent than the wild-type strain due to defective expression of the genes encoded by *Salmonella* pathogenicity islands \[[@R30], [@R31]\]. Recent studies have attributed tumor suppression by ΔppGpp *Salmonella* to a marked increase in production of proinflammatory cytokines, namely, TNF-a and IL-1b, by macrophages and dendritic cells infiltrated into the tumor mass \[[@R32], [@R33]\].

Although tumor targeting by bacteria alone results in a reduction of tumor mass \[[@R5], [@R9], [@R34]--[@R37]\], bacteria expressing therapeutic proteins are clearly more efficacious \[[@R30], [@R38], [@R39]\]. Because most anticancer proteins are to some degree also toxic to normal cells, their expression must be confined to tumor tissue. Following intravenous (*i.v.*) injection in mice, *Salmonella* rapidly accumulate in reticuloendothelial (RE) systems, liver, and spleen, but to a lesser extent in tumor tissue \[[@R38], [@R39]\]. Several days later, the *Salmonella* gradually clear from the RE systems but increase in number in tumor tissue at a rate that depends on the strain. This accumulation of *Salmonella* is due in part to the immune-suppressive environment in tumor tissue, which allows proliferation of intratumoral *Salmonella* to densities greater than 10^9^ colony-forming units (CFU)/g of tissue \[[@R40], [@R41]\]. Using ΔppGpp *Salmonella*, we observed that controlled expression of cytotoxic proteins such as cytolysin \[[@R42]\] or Noxa \[[@R43]\] 3 days post-infection (dpi) did not cause notable systemic toxicity.

L-asparaginase (L-ASNase, EC2) of *E. coli* origin is widely used in therapy of acute lymphoblastic leukemia (ALL) \[[@R44]\]. L-ASNase primarily catalyzes the deamination of asparagine to aspartate, and to a lesser extent the conversion of glutamine to glutamate \[[@R45]\]. In tumor cells defective in asparagine synthetase, depletion of asparagine leads to inhibition of global protein synthesis \[[@R46]\] due to a failure to resupply asparagine \[[@R47], [@R48]\], resulting in apoptotic cell death. L-ASNase administered via the intravenous (i.v.) route \[[@R47]\] is efficacious against ALL, but not against solid tumors, due to the limited distribution of the drug: L-ASNase injected i.v. rarely accumulates in grafted solid tumors in mouse models \[[@R49], [@R50]\]. Moreover, i.v. administration of high doses of L-ASNase to tumor-bearing mice results in morbidity and mortality, and the side effects associated with L-ASNase include anaphylactic shock, coagulopathies, and hepatic and pancreatic toxicity \[[@R50], [@R51]\].

Previously, we engineered *Salmonella* to express L-ASNase selectively within solid tumors using a remote gene control system based on the *araBAD* promoter (*P*BAD) of *E. coli*, which can be induced by intraperitoneal (i.p.) administration of L-arabinose. In mice harboring grafts of solid tumors, we demonstrated the antitumor efficacy of targeted L-ASNase using *Salmonella* transformed with this construct. Daily administration of L-arabinose was required to maintain continuous expression of L-ASNase. However, remote gene control via diffusion from the injection site had some intrinsic problems, including off-target effects and inhomogeneity. Frequent injection was also stressful for the animal. These inherent limitations of the *P*BAD-induced L-ASNase system mandated the development of a system in which L-ASNase is induced in a cell mass-dependent manner. To this end, we turned to a bacterial auto-induction system.

Certain species of bacteria exhibit cooperative behavioral patterns mediated by an environmental sensing mechanism termed the auto-induction system. This system allows bacteria to monitor their own population density by producing, secreting, and sensing a diffusible compound called the auto-inducer, whose concentration in the environment correlates well with local cell density during growth. At low cell densities, the auto-inducer is present at low concentrations, whereas at high cell densities it accumulates to the critical concentration required for activation of its target genes. For example, luminescence in the marine bacteria *Vibrio fischeri* and *Vibrio harveyi* is auto-induced by acyl-homoserine lactone (AHL). In this quorum-sensing (QS) system, the LuxI and LuxR proteins control expression of the luciferase operon (*luxICDABE*), which encodes the proteins required for luminescence. LuxI catalyzes the synthesis of the auto-inducer AHL \[[@R52], [@R53]\], whereas LuxR is the cytoplasmic AHL receptor that functions as a transcriptional activator upon ligand binding \[[@R54]\]. After synthesis *in vivo*, AHL freely diffuses in and out of bacterial cells, and its concentration increases with local cell density \[[@R55]\]. When AHL reaches a critical threshold concentration, the LuxR-AHL complex activates transcription of the operon encoding luciferase \[[@R56]\].

In this study, we engineered *S. typhimurium* harboring an auto-inducible recombinant plasmid expressing a gene encoding L-ASNase under the control of the *Vibrio* QS expression system, and demonstrated the bacterial density-dependent expression of L-ASNase and its antitumor effects in a mouse graft model.

RESULTS {#s2}
=======

Expression of reporter protein under the control of the QS promoter system {#s2_1}
--------------------------------------------------------------------------

The QS system (*luxR*, *luxI*, and *luxR--luxI* intergenic sequence including the *luxR* and *luxI* promoter) used in this study was deduced from the whole genome sequence of *Vibrio fischeri* and specifically amplified by PCR using primers listed in Table [1](#T1){ref-type="table"}. The resultant DNA fragments were assembled by overlapping PCR to exclude incorporation of additional bases, which occurs during typical subcloning procedures using restriction enzyme recognition sites. For efficient co-expression of transcriptionally coupled proteins (mCherry and L-ASNase) with LuxI, a well-known ribosome-binding sequence (RBS) from pQE30 was also included (Figure [1A](#F1){ref-type="fig"}). mCherry was deployed as a reporter to test the QS elements. Using this method, we constructed three different plasmids carrying the cell density-dependent expression system. pQSRI-mCherry consisted of *luxR* and the *luxR--luxI* intergenic sequence, including both promoters and mCherry transcriptionally coupled with *luxI*. pQSI-mCherry was the same except that it lacked *luxR.* pQSR-mCherry carried the mCherry gene under the direct control of *luxI* promoter, and thus lacked *luxI*, but retained intact *luxR*. The *glmS* gene was incorporated into these recombinant plasmids to generate a balanced-lethal host vector system \[[@R57]\] that complemented the phenotype of the GlmS^-^ mutant, which undergoes lysis unless its catalytic product N-acetyl-D-glucosamine is provided or complemented by a GlmS^+^-containing plasmid. These plasmids were transformed into an avirulent ΔppGpp *Salmonella typhimurium*, 14028s.

###### List of primer sequences used in this study

  Primer        Sequence(5′-3′)                                            Gene amplified
  ------------- ---------------------------------------------------------- ---------------------------------
  LuxRF         CGC**GGATCC**TTAATTTTTAAAGTATGGGCAATCAATTGC                *luxR*
  LuxROLR       AAGGATAAAGAGATGGGTATGAAAGACATAAATGCC                       
  LuxRIproF     CGC**GGATCC**CTCTTTATCCTTTATCCTTACCTATTG                   *luxR-luxI* intergenic sequence
  LuxRIproOLF   TTTCATACCCATCTCTTTATCCTTTATCCTTACCTATTG                    
  LuxIR         CTTGCTCACCATAGCTGTCCTCCTTTTTAATTTAAGACTGCTTTTTTAAACTGTTC   *luxI*
  LuxIproR      GAAAAACTCCATACCAACCTCCCTTGCGTTTATTC                        *luxR-luxI* intergenic sequence
  mChOLF        GTCTTAAATTAAAAAGGAGGACAGCTATGGTGAGCAAGGGCGAG               mCherry gene
  mChOL-RI F    AGGGAGGTTGGTATGGTGAGCAAGGGCGAG                             
  mChR          CGC**GTCGAC**TTACTACTTGTACAGCTCGTCC                        
  ASNOLF        GTCTTAAATTAAAAAGGAGGACAGCTATGGAGTTTTTCAAAAAGACGGCAC        L-Aspragenase gene
  ASNOL-RIF     AGGGAGGTTGGTATGGAGTTTTTCAAAAAGACGGCAC                      
  ASNR          CGC**GTCGAC**TTAGTACTGATTGAAGATCTGCTG                      
  glmSF         CC**ATCGAT**ATGTGTGGAATTGTTGGC                             *glmS*
  glmSR         CC**ATCGAT**TTACTCTACGGTAACCGATT                           

Restriction sites for *BamH*I (GGATCC), *Sal*I (GTCGAC) and *Cla*I (ATCGAT) are indicated in bold.

![Expression of mCherry reporter gene in ∆ppGpp Salmonella carrying pQSRI-mCherry, pQSI-mCherry, or pQSR-mCherry during growth *in vitro*\
(**A**) Plasmid constructs carrying mCherry under control of various combinations of QS elements, LuxR, and/or LuxI. (**B**) Bacterial growth (CFU/ml) in LB as a function of time (hours, h) (left panel). Expression of mCherry from bacteria grown in LB, as determined by fluorometry (right panel) and by Western blotting (bottom panel). For detection of mcherry, we used 20µg of purified protein for each sample. Positive control (P.C) is the sample of PQSRI-mcherry (12 hr). (**C**) *Salmonella* carrying the pQSRI-mCherry, grown in LB as shown in (Figure [1B](#F1){ref-type="fig"}, left panel), were sampled at the indicated time, stained, and imaged under a fluorescence microscope. Blue indicates DAPI staining and red indicates mCherry. Differential interference contrast (DIC) microscopic images of *Salmonella* are included. Scale bar, 10 µm. (**D**) mCherry-expressing *Salmonella* were quantitated ( \> 5 fields per sample) visually and plotted as a function of culture time. (**E**) Expression of mCherry by ∆ppGpp *Salmonella* carrying pQSRI-mCherry or pQSR-mCherry supplemented with or without AHL in LB, as determined by fluorometry. *Salmonella* carrying pQSR-mCherry were included as a control. Asterisks (^\*^) in panels B and D indicate significant differences compared to pQSI-mCherry (^\*\*\*^*P* \< 0.0001).](oncotarget-09-8548-g001){#F1}

*Salmonella* carrying these plasmids were cultured in Luria-Bertani (LB) media, and samples were collected at the indicated times (h) to determine viable cell count (CFU, Figure [1B](#F1){ref-type="fig"}, left panel) for analysis of mCherry expression by fluorometry (Figure [1B](#F1){ref-type="fig"}, right panel) and for Western blotting using mCherry-specific antibody (Figure [1B](#F1){ref-type="fig"}, bottom panel). The results revealed that *Salmonella* carrying pQSRI-mCherry began to show fluorescence at ∼3 h, which saturated at 9 h as the culture density rose above 10^9^ CFU/ml, whereas those carrying pQSI-mCherry or pQSR-mCherry expressed no fluorescence. The expression of mCherry by *Salmonella* carrying pQSRI-mCherry was visualized by fluorescence microscopy (Figure [1C](#F1){ref-type="fig"}). Bacterial cells expressing mCherry fluorescence began to be detected starting at ∼4 h and increased in number as time passed. Figure [1D](#F1){ref-type="fig"} shows quantitation of the fluorescent *Salmonella* shown in Figure [1C](#F1){ref-type="fig"}. *Salmonella* carrying pQSR-mCherry failed to express mCherry because they lacked LuxI and were thus unable to produce auto-inducer \[[@R52]\]. Accordingly, addition of AHL to the media restored mCherry expression (Figure [1E](#F1){ref-type="fig"}), albeit only partially, as expected. Taken together, these observations demonstrate that a cargo gene transcriptionally coupled with *luxI* in the presence of LuxR can be expressed in a cell density-dependent manner.

Subsequently, we determined the expression and distribution of mCherry expressed by tumor-targeted *Salmonella* carrying pQSRI-mCherry in C57BL/6 mice bearing MC38 tumors (Figure [2](#F2){ref-type="fig"}). *Salmonella* (1 × 10^7^ CFU) were injected through the tail vein when the tumor implanted in the right lateral thigh reached ∼120 mm^3^. Mice were sacrificed on 1 and 5 dpi (days post-infection). The excised tumors were subjected to immunofluorescence staining and analyzed for *Salmonella* and mCherry expression. The number of *Salmonella* in tumor tissue was in the range of 10^7^--10^8^ CFU/g in tumor tissue on 1 dpi, and a bit higher on 5 dpi, whereas the number in liver and spleen was considerably lower, between 10^3^ and 10^4^ CFU/g tissue in liver during the same time period (Figure [2A](#F2){ref-type="fig"}). mCherry expression was abundant in tumor tissue at 5 dpi, mostly overlapping with *Salmonella*, but much less abundant at 1 dpi. By contrast, in the reticular endothelial system, very little mCherry was detected (Figure [2B](#F2){ref-type="fig"}). These results confirmed QS-dependent mCherry expression in an animal system.

![Expression of mCherry by a quorum-sensing promoter in a mouse tumor model (*n* = 3)\
(**A**) Bacteria in liver, spleen, and tumor tissues were counted at the indicated days by determining CFU. (**B**) Expression of mCherry from intratumoral *Salmonella* carrying pQSRI-mCherry was detected by fluorescence microscopy at the indicated dpi. Expression of mCherry (red) in tumor tissues was analyzed after staining of *Salmonella* with a specific antibody (green) and nuclei with DAPI (blue) in each sample. Scale bar, 20 µm.](oncotarget-09-8548-g002){#F2}

Expression and secretion of ASNase from Salmonella carrying pQSRI-ASNase {#s2_2}
------------------------------------------------------------------------

To develop a strain useful for treating solid malignancies using a cell density-dependent inducible QS system, the mCherry gene in the above constructs was replaced with the L-ASNase gene of *E. coli B* (BL21) \[[@R58]\]. To this end, we prepared three constructs, pQSRI-ASNase, pQSI-ASNase, and pQSR-ASNase (Figure [3A](#F3){ref-type="fig"}), and introduced them into the host bacteria. These engineered *Salmonella* were grown in LB media, and samples were taken at the indicated times. The cells were harvested by centrifugation and analyzed for L-ASNase expression by Western blotting using a specific antibody (Figure [3B](#F3){ref-type="fig"}). L-ASNase was induced in a cell density-dependent manner only in *Salmonella* carrying pQSRI-ASNase. The culture medium of *Salmonella* carrying pQSRI-ASNase was also harvested, and secreted protein in the medium was analyzed by Western blotting. As shown in Figure [3B](#F3){ref-type="fig"} (bottom row), we detected a distinct band corresponding to L-ASNase. These results indicated that L-ASNase was induced at an appropriate cell density, and that a significant fraction (∼55%) was secreted into the media, as demonstrated previously \[[@R50]\]. The cell density-dependent expression of L-ASNase was verified by determining the enzyme activity in *Salmonella* growing in LB medium (Figure [3C](#F3){ref-type="fig"}).

![Expression of L-ASNase in ∆ppGpp Salmonella carrying pQSR-ASNase, pQSI-ASNase, or pQSRI-ASNase during growth *in vitro*\
(**A**) Plasmid constructs carrying ASNase under control of different combinations of QS elements, LuxR, and/or LuxI. (**B**) *Salmonella* carrying the indicated plasmids were grown in LB, and bacterial samples (pellets) were taken for analysis of L-ASNase expression by Western blotting. The last row shows L-ASNase secreted from *Salmonella* carrying pQSRI-ASNase into media (supernatant). (**C**) L-ASNase activities from *Salmonella* carrying the indicated plasmids. Asterisks (^\*^) indicate significant differences vs. pQSI-mCherry (^\*\*\*^*P* = 0.0005, ^\*\*\*\*^*P* \< 0.0001). (**D**) *Salmonella* were grown to stationary phase (9 hr) in LB (bacteria carrying pQSRI-ASNase) or in LB with or without 0.2% L-arabinose (bacteria carrying P~BAD~::ASNase). Equal amounts of bacterial cultures were harvested, separated into pellet and supernatant fractions, and analyzed for L-ASNase by Western blotting (upper panel) or an assay kit (supernatants only; lower panel). Asterisks (^\*^) indicate significant differences vs. pBAD24 plasmid (Mock) (^\*\*\*^*P* = 0.0004, ^\*\*\*\*^*P* \< 0.0001).](oncotarget-09-8548-g003){#F3}

Previously, we engineered *Salmonella* expressing L-ASNase under the control of *P*BAD of the *E. coli* arabinose operon, which can be induced with L-arabinose (P~BAD~::ASN), and demonstrated its effects on various solid tumors in a mouse model \[[@R50]\]. In this study, we compared the expression of L-ASNase from pQSRI-ASNase with that from P~BAD~::ASN. For this purpose, *Salmonella* carrying pQSRI-ASNase were grown in LB medium, and cells carrying P~BAD~::ASN were grown in LB media with or without 0.2% L-arabinose. Equal amounts of bacterial cultures were harvested and separated into two fractions, bacterial pellet and media supernatant, and L-ASNase levels were analyzed by Western blotting (Figure [3D](#F3){ref-type="fig"} upper image). Addition of L-arabinose significantly induced L-ASNase expression in *Salmonella* carrying P~BAD~::ASNase at levels comparable to those expressed from *Salmonella* carrying pQSRI-ASNase grown in LB medium for 9 h. In both cases, more than half of L-ASNase was secreted out of the bacterial cells, which can be ascribed to the extracellular nature of the protein \[[@R59]\]. This was further corroborated by determination of L-ASNase enzyme activities in the same bacterial medium: the levels were very low in *Salmonella* carrying P~BAD~::ASN without induction, and the levels were higher (and comparable) in *Salmonella* carrying P~BAD~::ASN induced by L-arabinose and those carrying pQSRI-ASNase (Figure [3D](#F3){ref-type="fig"} lower graph).

Antitumor effect of L-ASNase expressed by Salmonella carrying pQSRI-ASNase {#s2_3}
--------------------------------------------------------------------------

Next, we determined the antitumor effect of L-ASNase expressed and secreted by *Salmonella* carrying pQSRI-ASNase *in vitro*, using cultured mouse MC38 colon cancer cells. *Salmonella* carrying pQSR-ASNase or pQSI-ASNase were cultured for 9 h, and then the media were separated and concentrated. Concentrated media were added to cultured MC38 cells at final concentrations of 0.2 mg/ml, and then incubated for 24 h. MC38 cell viability was determined by MTT assay (Figure [4A](#F4){ref-type="fig"}). Media from *Salmonella* carrying pQSRI-ASNase killed almost all (99%) cells, whereas media from bacteria carrying other plasmids had little effect on viability. The cytotoxic effect of L-ASNase was also examined by TUNEL assay (Figure [4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}). Over 90% of MC38 cells incubated with media from *Salmonella* carrying pQSRI-ASNase were TUNEL-positive; again, the other bacterial strains had minimal effect. Taken together, these data indicate that L-ASNase expressed and secreted under the control of the QS system is highly toxic to MC38 cancer cells *in vitro*.

![Cytotoxic effect of L-ASNase secreted from Salmonella carrying pQSRI-ASN, pQSI-ASN, or pQSR-ASNase\
(**A** and **B**) *Salmonella* carrying the indicated plasmids were grown in LB for 9 hr. Bacterial supernatants were separated and concentrated to 200 mg/ml. MC38 cells were treated with the supernatants for 24 hr, and cell viability was determined by MTT assay \[A\] and TUNEL assay \[B\]. Asterisks (^\*^) indicate significant differences vs. Mock (^\*\*\*^*P* = 0.0004). (**C**) Quantitation of TUNEL-positive cells. Mock was with *Salmonella* carrying vector pBAD plasmid. Asterisks (^\*^) indicate significant differences compared to Mock or pQSR-ASN and pQSI-ASN (^\*\*\*^*P* = 0.0005).](oncotarget-09-8548-g004){#F4}

Subsequently, we assessed the antitumor efficacy of *Salmonella* carrying pQSRI-ASNase, pQSR-ASNase, or pQSI-ASNase in C57BL/6 mice bearing MC38 tumors. *Salmonella* carrying pQSRI-ASNase had the highest antitumor efficacy (Figure [5A, 5B](#F5){ref-type="fig"}). *Salmonella* carrying pQSR-ASNase or pQSI-ASNase had a slightly stronger effect than the phosphate-buffered saline (PBS)-treated control, which could be ascribed to the anticancer effect of *Salmonella* itself \[[@R9], [@R36]\]. Tumors reached a mean size of 1,000 mm^3^ by day 4 following PBS treatment and by day 8 following treatment with *Salmonella* carrying either pQSR-ASNase or pQSI-ASNase. By contrast, tumors in mice treated with *Salmonella* carrying pQSRI-ASNase were less than 500 mm^3^ at the end of the experiment (day 14). Consistent with this, survival was considerably longer in animals that received *Salmonella* carrying pQSRI-ASNase than in the other groups (Figure [5C](#F5){ref-type="fig"}).

![Antitumor effects of Salmonella carrying pQSRI-ASNase, pQSI-ASNase, or pQSR-ASNase *in vivo*\
The antitumor effect of *Salmonella* (1 × 10^7^ CFU) carrying the indicated plasmids was measured using MC38 tumors grafted into C57BL/6 mice (*n* = 7 for each treatment). Treatment with PBS was included as a negative control (*n* = 7). (**A**) Representative gross morphological changes. (**B**) Changes in tumor size after bacterial treatment. Error bars correspond to 95% confidence interval (CI). Asterisks (^\*^) indicate significant differences vs. treatment with PBS (^\*\*\*^*P* = 0.006). (**C**) Kaplan−Meier survival curves of mice bearing MC38 tumors. Asterisks (^\*^) indicate significant differences vs. treatment with PBS (^\*^*P* = 0.01, ^\*\*^*P* = 0.0013, ^\*\*\*^*P* = 0.0003).](oncotarget-09-8548-g005){#F5}

Analysis of L-ASNase levels in tumor tissues from mice treated with *Salmonella* carrying pQSRI-ASNase (Figure [6](#F6){ref-type="fig"}) revealed little L-ASNase at 1 dpi, but a considerable level at 5 dpi, as assessed by Western blotting with a specific antibody (Figure [6A](#F6){ref-type="fig"}, *n* = 4) and immunofluorescence microscopy (Figure [6B](#F6){ref-type="fig"}). Notably, L-ASNase co-localized with *Salmonella* in a density-dependent manner, i.e., L-ASNase was detected in areas with dense *Salmonella* populations (Figure [6B](#F6){ref-type="fig"}). Based on these findings, we conclude that L-ASNase expressed in a bacterial density-dependent manner effectively suppressed solid tumor growth in our mouse model.

![*In situ* expression of L-ASNase by quorum-sensing promoter in a mouse tumor model\
Expression of L-ASNase in mice treated with *Salmonella* carrying pQSRI-ASNase was analyzed at 1 and 5 dpi by Western blotting (*n* = 4 for each group, (**A**) or by immunofluorescence microscopy (80× magnification) (**B**). Green indicates *Salmonella* and red indicates L-ASNase. Scale bar, 50 µm.](oncotarget-09-8548-g006){#F6}

DISCUSSION {#s3}
==========

Successful application of cancer therapy using bacteria expressing a genetically engineered anticancer protein requires that the active agent be conditionally expressed in tumor tissue, leaving the reticular endothelial system undamaged. In this study, we developed and employed an expression system that is activated in a bacterial density-dependent manner, causing the therapeutic protein under its control to be expressed only when bacterial cell density rises above a threshold level (at least 10^8^ CFU/ml, Figure [1B](#F1){ref-type="fig"}). Bacterial cell densities in healthy liver and spleen remained below 10^4^ CFU/g. *In vitro* experiments showed that *luxI* promoter-driven expression of the cargo gene was activated as the cultures entered stationary phase, as bacterial cell density rose above ∼10^9^ CFU/ml in liquid culture (Figure [1B](#F1){ref-type="fig"}). This induction was dependent on AHL produced by LuxI and its cognate binding protein LuxR. This theory was corroborated by restoration of induction by addition of exogenous AHL into the culture medium of *Salmonella* carrying pQSR-mCherry (Figure [1E](#F1){ref-type="fig"}).

Examination of the expression of mCherry and L-ASNase in intratumoral *Salmonella* at 1 and 5 dpi by IF microscopy (Figures [2](#F2){ref-type="fig"} and [6](#F6){ref-type="fig"}) revealed greater abundance at 5 dpi than 1 dpi, but significantly more mCherry/L-ASNase expression at 5 dpi in the area where *Salmonella* had accumulated heavily (Figures [2B](#F2){ref-type="fig"} and [6](#F6){ref-type="fig"}). This pattern of expression suggested that AHL reached the critical concentration only in these areas of high *Salmonella* density. Consistent with this, little mCherry expression was detected in the reticular endothelial system. A similar study using *Salmonella* carrying an episomal *luxI* promoter--*luxR--GFP--luxI* construct \[[@R60]\] concluded that GFP expression by intratumoral *Salmonella* colonies depended on the distance between neighboring bacteria; no colonies expressed GFP when the average distance to neighbors was greater than 155 µm. Thus, this QS-dependent induction system is far superior to the *P*BAD system of *E. coli*, which provides a remote control system by which a tumor-toxic protein can be induced by i.p. administration of L-arabinose \[[@R37], [@R42], [@R50]\]. Consequently, sustained expression of the cargo protein by intratumoral bacteria requires repeated administration of L-arabinose. As demonstrated in this study, QS-dependent induction of the L-ASNase by intratumoral *Salmonella* provides a simple method for sustained expression of a protein drug without requiring supplementation with an exogenous inducer, and achieved notable retardation of tumor growth and delay of mortality in tumor-bearing mice (Figure [5](#F5){ref-type="fig"}).

MATERIALS AND METHODS {#s4}
=====================

Bacterial strains, plasmids, and culture conditions {#s4_1}
---------------------------------------------------

The *E. coli* strain used in this study for gene manipulation was XL1-Blue. The QS expression module of *Vibrio fischeri* was derived from the sequence deposited in GenBank (AF170104.1). The expression plasmid pBAD24 (Invitrogen, USA) was chosen as a scaffold for construction of the QS expression system in *Salmonella*. The *Salmonella* strain used in this study, the ppGpp-defective strain SHJ2037 (*relA::cat*, *spoT::kan*), was derived from the wild-type *Salmonella enterica* serovar *Typhimurium* 14028s, and was described previously \[[@R27], [@R61]\]. This strain is also *GLmS* ^--^, and therefore requires N-acetylglucosamine for growth unless complemented by a *GLmS* ^+^-containing plasmid \[[@R57]\].

Recombinant *Salmonella* were grown at 37°C in LB medium containing 1% NaCl. For solid support medium, 1.5% Bacto agar was included. All media were supplemented with an antibiotic (ampicillin, 100 µg/ml) and/or AHL (0.05--1 mM) as needed.

Construction of recombinant plasmids with various genes under the control of the QS expression system {#s4_2}
-----------------------------------------------------------------------------------------------------

To express target genes under the control of the QS system, the expression vector pQS was constructed using pBAD24 as a scaffold. The primer pair LuxRF/LuxROLR (Table [1](#T1){ref-type="table"}) was designed to amplify the gene encoding LuxR (accession no. AAD48473.1); the primer pair luxRI proOLF/LuxIR was used to generate a construct that fuses the *luxR--luxI* intergenic sequence with *luxI* gene (accession no. AAD48474.1). As a functional reporter, the gene encoding mCherry (Takara Bio, USA) was also amplified using primer pair mChOLF/mChR. The three amplicons were assembled by overlapping PCR, and then subcloned into the *Bam*HI/*Sal*I site of pBAD24 to yield pQSRI-mCherry (Figure [1A](#F1){ref-type="fig"}). The recombinant plasmid pQSI-mCherry was prepared as follows: primers luxRI proF and LuxIR were used to generate a construct that fuses the *luxR--luxI* intergenic sequence with the *luxI* gene. This DNA fragment was assembled by PCR using the same mCherry gene described above. The resultant DNA fragment was subcloned into the *Bam*HI/*Sal*I site of pBAD24. pQSR-mCherry was also constructed by overlapping PCR with two constructs, a DNA fragment containing *luxR* and the *luxR--luxI* intergenic sequence amplified by PCR with primers LuxRF and LuxRI proR, and a DNA fragment containing mCherry amplified with primers mChOL-RIF and mChR. The resultant construct was also subcloned into the *Bam*HI/*Sal*I site of pBAD24. For stable maintenance *in vivo* without exogenous inducer, the *glmS* gene was amplified with primers *glmSF* and *glmSR* primers from genomic DNA of *Salmonella* and inserted into the vector at the *Cla*I site.

To evaluate these constructs as a genetically encoded drug expression system *in vivo*, the three plasmids pQSRI-ASNase, pQSI-ASNase, and pQSR-ASNase, in which the mCherry gene was replaced with the gene encoding ASNase, were constructed using the procedure described above (Figure [3A](#F3){ref-type="fig"}). These constructions used DNA fragments amplified with primer pairs ASN OLF/ASN R and ASN OL-RIF/ASN R. All constructs were confirmed by DNA sequencing and functionally tested in both *E. coli* XL1-Blue and DppGpp *S. typhimurium*.

Preparation of L-ASNase {#s4_3}
-----------------------

To monitor the intracellular expression level of L-ASNase, recombinant bacteria were harvested by centrifugation at 5,000 × *g* for 5 min and lysed by sonication in lysis buffer (10 mM lysozyme, 10% sodium dodecyl sulfate). The resultant solution was further centrifuged at 13,000 × *g* for 30 min, and the supernatant was collected, filtered (0.22 µm pore size), and concentrated using a Centricon device (Amicon^®^ Ultra, 10K pore filter, Millipore). The proteins were precipitated with 10% trichloroacetic acid (TCA) for 1 hr at 4°C, and the pellets were re-dissolved in PBS for analysis of secreted L-ASNase.

Cell culture and viability assay {#s4_4}
--------------------------------

MC38 cells were grown in high-glucose Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin--streptomycin.

Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Briefly, 100 μl cell suspension was inoculated in each well of a 96-well plate at a density of 2 × 10^4^ cells/well. After 24 hr of culture, the medium was removed by aspiration and replaced with 100 μl experimental medium, and the cells were cultured for an additional 24 hr. MTT solution (10 μl) was added to each well, and the plates were incubated in the dark for 4 hr at 37°C. The number of remaining viable cells (i.e., cells with MTT dye) was determined by measuring the optical density at 490 nm in an enzyme-linked immunosorbent assay reader.

TUNEL assays {#s4_5}
------------

*Salmonella* carrying pQSRI-ASNase, pQSI-ASNase, or pQSR-ASNase were cultured in LB for 24 hr. Bacterial supernatants were harvested as described above. MC38 cells were incubated with the bacterial supernatants (0.2 mg/ml) for 24 hr, fixed in 4% paraformaldehyde (PFA), and analyzed using the DeadEnd colorimetric TUNEL analysis kit (Promega, Madison, WI, USA).

Immunofluorescence staining {#s4_6}
---------------------------

Tumor tissues were fixed overnight at room temperature with 4% PFA in PBS. Samples were embedded and frozen in optical Optimal Cutting Temperature compound (OCT, Tissue-Tek), and then sliced into 6 mm sections using a microtome-cryostat. Tissue sections were collected on aminopropyl triethoxysilane-coated slides. The slides were washed in PBS (pH 7.4) and incubated with primary antibody, rabbit anti-asparaginase (1:100, Abcam, ab28364), and mouse anti-*Salmonella* (1:100, Abcam, ab8274) overnight at 4°C. Subsequently, Alexa Fluor 488-conjugated goat anti-rabbit (1:100) and Alexa Fluor 568-conjugated goat anti-mouse (1:100) antibodies were used as secondary antibodies. After staining of nuclei with DAPI/Antifade (1:200, Invitrogen), the samples were mounted.

Western analysis {#s4_7}
----------------

Mammalian cell lines and tumor tissues were lysed by sonication in RIPA buffer (50 mM Tris-HCl \[pH 7.5\], 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS) containing protease inhibitors (protease inhibitor mixture; Roche Applied Science). Tumor tissues were extracted, homogenized with a motor-driven tissue homogenizer (Ika-Werke, Staufen, Germany), and separated into supernatant and pellet by centrifugation (5,000 × *g*, 5 min). Pellets were lysed by sonication as described above. The supernatants were treated with 10% TCA (1 hr, 4°C) to precipitate proteins. For Western blot analysis, protein samples were boiled for 5 min, separated by 10% SDS--polyacrylamide gel electrophoresis (PAGE), and transferred to nitrocellulose membrane (Amersham Biosciences, Buckinghamshire, UK). The membrane was blocked with 5% skim milk, probed at 4°C overnight with rabbit anti- mcherry antibody (1:1000; abcam), rabbit anti-asparaginase antibody (1:1,000; Abcam) or mouse anti-b-Actin antibody (1:5,000, Santa Cruz Biotechnology), and then incubated with anti-mouse or anti-rabbit IgG linked to horseradish peroxidase (Sigma-Aldrich, UK) for 1 hr, respectively. Bound proteins were visualized using the ECL kit (Amersham Biosciences).

Animal experiments {#s4_8}
------------------

Five- to six-week-old male mice (20--30 g body weight) were purchased from Samtako (Korea). When the tumor reached ∼120 mm^3^, 1 × 10^7^ CFU ∆ppGpp *S. typhimurium* transformed with the indicated plasmids were suspended in PBS and injected through the tail vein. All animal care, experiments, and euthanasia were performed in accordance with protocols approved by the Chonnam National University Animal Research Committee. Animals were anesthetized with isoflurane (2%) for imaging or a mixture of ketamine (200 mg kg^-1^) and xylazine (10 mg kg^-1^) for surgery. Mice carrying subcutaneous tumors were generated as follows: tumor cells cultured *in vitro* were harvested, suspended in 100 µl PBS, and injected subcutaneously into the right thigh (1 × 10^6^ cells for MC38). Tumor volumes (mm^3^) were estimated using the formula (L × H × W)/2, where L is the length, W is the width, and H is the height of the tumor in millimeters.

L-ASNase activity assay {#s4_9}
-----------------------

Bacterial supernatants containing L-ASNase were prepared in concentrated forms for the enzymatic assay. Tumor tissue samples were extracted with four volumes of assay buffer from the Asparaginase Activity Assay kit (Abcam, ab107922), and insoluble materials were removed by centrifugation. Levels of L-ASNase enzymatic activity in bacterial supernatants (100 µg) and tumor tissues (100 µg) were assessed using the Asparaginase Activity Assay kit.

Statistical analysis {#s4_10}
--------------------

Statistical analysis was performed using the SPSS 18.0 statistical package (SPSS Inc., Chicago, IL, USA). The two-tailed Student's *t-*test was used to assess the statistical significance of tumor growth and differences in survival between treatment groups. *P* \< 0.05 was considered statistically significant.
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